Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
Recruiting · NCT05319639 · Registry updated 2025-02-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 1 / Phase 2 | 2025-02-27 | NCT05319639 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fujian Cancer Hospital | 114 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fujian cancer hospital | Fuzhou | China | 4 |